3-(2-Methyl-1,3-thiazol-4-yl)benzaldehyde → 6-(2,3-Dihydrobenzo[b][1,4]dioxin-5-yl)-1-(3-(2-methylthiazol-4-yl)benzyl)piperidin-2-one
反応式
[NH2:1][CH:2]([C:10]1[C:19]2[O:18][CH2:17][CH2:16][O:15][C:14]=2[CH:13]=[CH:12][CH:11]=1)[CH2:3][CH2:4][CH2:5][C:6]([O:8]C)=O.[CH3:20][C:21]1[S:22][CH:23]=[C:24]([C:26]2[CH:27]=[C:28]([CH:31]=[CH:32][CH:33]=2)[CH:29]=O)[N:25]=1>>[O:15]1[CH2:16][CH2:17][O:18][C:19]2[C:10]([CH:2]3[N:1]([CH2:29][C:28]4[CH:31]=[CH:32][CH:33]=[C:26]([C:24]5[N:25]=[C:21]([CH3:20])[S:22][CH:23]=5)[CH:27]=4)[C:6](=[O:8])[CH2:5][CH2:4][CH2:3]3)=[CH:11][CH:12]=[CH:13][C:14]1=2参加物
3
実験手順
Prepared according to the described general procedure 1 (GP1) by reaction of methyl 5-amino-5-(2,3-dihydrobenzo[b][1,4]dioxin-5-yl)pentanoate with commercially available 3-(2-methylthiazol-4-yl)benzaldehyde. Subsequent purification by preparative HPLC afforded the target compound. LC-MS (conditions A): tR=0.81 min.; [M+H]+: 420.98 g/mol.
後処理
- customPrepared
- customSubsequent purification by preparative HPLC
- custom